MAPT mutations were the first discovered genetic cause of frontotemporal dementia (FTD) in 1998. Since that time, over 60 MAPT mutations have been identified, usually causing behavioural variant FTD (bvFTD) and/or parkinsonism clinically. We describe two novel MAPT mutations, D252V and G389_I392del, each presenting in a patient with bvFTD and associated language and cognitive deficits. Neuroimaging revealed asymmetrical left greater than right temporal lobe atrophy in the first case, and bifrontal atrophy in the second case. Disease duration was 8 years and 5 years respectively. Post mortem examination in both patients revealed a 3-repeat predominant tauopathy, similar in appearance to Pick's disease. These two mutations add to the literature on genetic FTD, both presenting with similar clinical and imaging features to previously described cases, and pathologically showing a primary tauopathy similar to a number of other MAPT mutations.
Background
Frontotemporal dementia (FTD) is a clinically and pathologically heterogeneous group of neurodegenerative disorders (Woollacott 2016). Around one third of FTD is familial, with the first gene identified as having causative mutations being microtubule-associated protein tau (MAPT) in 1998 (Hutton et al, 1998 , Poorkaj et al, 1998 , Spillantini et al, 1998 ). Since that time over 60 MAPT mutations have been discovered, with the majority presenting with clinical features of behavioural change and/or parkinsonism (Greaves et al, 2019) . Other symptoms include semantic impairment (although it is rare for language problems to be the presenting feature) and, unlike most other forms of FTD, episodic memory difficulties (Tolboom et al, 2010; Liang et al, 2014) . Age of symptom onset is variable (although is commonly in the 40's or 50's), as is disease duration, which can vary from between a few years and over twenty (Ygland et al, 2018) . Pathologically, there is also heterogeneity: often both 3-repeat (3R) and 4-repeat (4R) isoforms of tau are found in the neuronal and glial inclusions at post mortem but for some mutations 3R-tau inclusions are predominant whilst others have predominantly 4R-tau (Ghetti et al, 2015) . In this case series we report two individuals who presented with FTD and were found to have novel pathogenic MAPT mutations with subsequent pathological confirmation of a primary tauopathy.
Methods

Clinical
Both patients attended the Specialist Cognitive Disorders Clinic at the National Hospital for Neurology and Neurosurgery where they underwent a standard clinical and neuropsychological assessment. Magnetic resonance imaging was performed on a 3T Siemens Trio scanner.
Genetics
Blood was taken for genetic testing in both patients with informed consent. 
Neuropathology
Both patients consented to brain donation at the Queen Square Brain Bank for Neurological Disorders (QSBB). After death the brains were processed according to QSBB protocol, which involves freezing of the right brain hemisphere, and fixation in 10% buffered formalin with tissue sampling and processing for paraffin histology of the left hemisphere. All tissues are stored at QSBB under a licence from the Human Tissue Authority. Sections of 7 µm thickness were cut from formalin-fixed paraffin-embedded tissue blocks from multiple brain regions, mounted on glass slides and stained with haematoxylin and eosin (H&E).
Representative sections were examined with immunohistochemical stains with the following antibodies: phospho-tau (AT8 MN1020, 1:600; Thermo), Aβ (6F3D, 1:100; Dako), α-synuclein (ab80627, 1:1500; Abcam), TDP-43 (2E2-D3, 1:5000; Abnova), 4R tau (1E1/A6, 1:4000; Millipore) and 3R tau (8E6/C11, 1:800; Millipore). All immunostainings were carried out on an automated immunostaining machine (A.Menarini Diagnostics) following manufacturer's guidelines using 3,3′-diaminobenzidine as chromogen and appropriate positive and negative controls. Ethical approval for the study was obtained from the Local Research Ethics Committee of the National Hospital for Neurology and Neurosurgery.
Results
Case 1
Clinical history
A 46-year-old right-handed gentleman presented to his local neurologist with a one year history of behavioural change and impairment of language and cognition. He had become more socially withdrawn and apathetic with poor self-care. He had also become more obsessive with a preference for routines. Over the same time period he had had difficulty with understanding the meaning of words and had developed difficulties with recognising both faces and familiar places, the latter impairment leading to him getting lost at times. He was otherwise fit and well without any other medical problems.
The presentation led to a referral to our clinic where he underwent a detailed cognitive assessment. His speech was noted to be fluent but empty of content with repeated use of There was a strong family history of dementia with his mother developing 'dementia' in her 70's, and all but one of her seven siblings also developing 'dementia' in their 60's or 70's.
Little was known about the phenotype of his relatives.
MR imaging ( Fig 1A) showed bilateral anterior temporal lobe atrophy, particularly affecting the medial temporal lobes including the amygdala and anterior hippocampus, more marked on the left than the right. There was less marked frontal lobe involvement, but particularly involving the left orbitofrontal cortex.
A diagnosis of FTD with both behavioural symptoms and prominent semantic impairment was made at this time.
He was reviewed twice over the next year. Worsening behaviour was noted with hoarding, development of a sweet tooth and inappropriate trusting behaviour. Comprehension had deteriorated with difficulties communicating effectively by the last appointment. He was not seen again in the clinic, requiring full time care from this point. He died five years later at the age of 54.
Genetics
The patient was found to carry a novel missense variant in exon 9 of the MAPT gene: 
Neuropathology
Macroscopically, with a whole brain weight of approximately 830g, there was global atrophy with emphasis in the temporal and frontal lobes, with widespread cortical thinning, reduction in white matter bulk and severe dilation of the lateral and 3 rd ventricles (Figure 2 , A1-A3). The caudate nucleus showed severe atrophy and the globus pallidus was darkly discoloured whilst the putamen was only mildly reduced in size (Figure 2 , A2). The thalamus showed a reduction in size (Figure 2, A3 ), but the subthalamic nucleus appeared normal. There was very severe atrophy of the hippocampus and the amygdala was not discernible due to the extremely severe atrophy (Figure 2 particularly widespread atrophy of the dentate gyrus. Across the medial temporal lobe there were phospho-tau (AT8) and 3R-tau positive neuropil threads, Pick bodies, neurofibrillary tangles and pre-tangles (Figure 2, A13-A14 ). In the severely atrophic caudate, the less atrophic globus pallidus, putamen and thalamus, there was a dense phospho-tau and 3R-tau immunoreactive neuropil thread and globular and globose neuronal cytoplasmic tau pathology. Severe neuronal loss with free pigment deposition and prominent chronic gliosis was seen in the substantia nigra accompanied by dense phospho-tau immunoreactive thread and tangle pathology across the midbrain. The corticospinal tracts across the brain stem showed severe atrophy. Whilst the overall cerebellar cytoarchitecture was preserved, scanty tau pathology was seen in the cerebellar white matter, with more frequent threads and pretangles evident across the dentate nucleus. Histological examination revealed no evidence of Aβ, α-synuclein or TDP-43 pathology and assessment of Braak & Braak neurofibrillary tangle stage was not feasible due to the presence of the primary tauopathy.
Case 2
Clinical history
A 49-year-old woman presented to our clinic with a 2-year history of behavioural change, language impairment and poor planning and decision making. She had become more apathetic with a decline in self-care. There was increasing word-finding difficulty with problems at home suggestive of executive dysfunction e.g. difficulties following instructions and difficulty operating the cooker. The patient's mother died in middle age without a diagnosis of dementia, though aggressive behavior was reported. However, her mother's mother developed dementia with behavioural change in her early 50's, dying at the age of 70. She was then seen a further two years later by which time she required full time care and was doubly incontinent with impaired mobility. She was not seen again in the clinic and died 2 years later at the age of 54.
Genetics
The patient was found to carry a novel variant in exon 13 of the MAPT gene: NM_001123066.3: c.2171_2182del: p.Gly724_Ile727del. In some nomenclatures of the MAPT gene this is known as p.G389_I392del. This is a heterozygous deletion of twelve nucleotides leading to a deletion of 4 amino acids. Conservation assessment of the deleted region using phastCons produced scores between 0.901 and 1 reflecting a high probability of the deleted nucleotides belonging to a conserved element of the genome. Using CADD to predict the deleteriousness of this variant we obtained a normalized PHRED score of 21.5, indicating this variant is predicted to be in the top 1% of the most deleterious variants in the human genome. Of note, two point mutations, both reported to be pathogenic, have been previously 
Neuropathology
Macroscopically, with a whole brain weight of approximately 970g, there was severe frontal and anterior and medial temporal lobe atrophy with a thin and discoloured cortical ribbon ( Figure 2, B1, B2, B3 ). There was also prominent atrophy of the inferior parietal lobule and enlargement of the frontal horn of the lateral ventricle, and to a lesser extent, the 3 rd ventricle. All deep brain nuclei were mildly reduced in size (Figure 2, B2, B3 ). Prominent atrophy of the amygdala and hippocampus was observed, but the superior temporal and Heschl's gyri were preserved in bulk (Figure 2, B3) . The bulk of the brainstem was reduced and the fronto-pontine tracts in the midbrain and corticospinal tracts in the pons showed marked atrophy. The substantia nigra showed pallor rostrally at the level of the red nucleus ( Figure 2, B4) , and also locus coeruleus was pale. The cerebellum was unremarkable.
Microscopically, there was very severe pan-cortical atrophy of the anterior frontal lobe, middle temporal (but not superior temporal or Heschl's) gyri (Figure 2, B7 and B11 ) and inferior parietal lobule. Immunostaining for phospho-tau (AT8) confirmed a primary tauopathy with a dense meshwork of pan-cortical neuropil threads and frequent globular 3R-tau immunoreactive neuronal inclusions (Pick bodies) across the frontal, temporal and parietal lobes. 3R-tau immunostaining also highlighted occasional astrocytic inclusions, whilst 4R-tau positive inclusions were absent (Figure 2, B8, B9, B10 and B12 ). Tau pathology in the form of scattered threads and occasional coiled bodies was also seen in the subcortical white matter of frontal, temporal and parietal lobes. The atrophic hippocampus and amygdala contained dense tau positive thread and tangle pathology with frequent 3R-tau positive threads and Pick bodies and globose tangles in the residual neurones (Figure 2, B13 and B14). Dense neuropil thread and frequent neuronal tangle and Pick body pathology was seen throughout the caudate, Meynert nucleus, internal part of the globus pallidus and medial aspect of the putamen, with comparably less tau pathology in the external part of the globus pallidus, lateral aspect of the putamen and thalamus. The mildly atrophic substantia nigra, locus coeruleus and pontine base contained widespread tau pathology in the form of neuropil threads and tangles. In the cerebellum there were moderate numbers of pre-tangles and neuropil threads in the dentate nucleus, with no apparent tau pathology in the cerebellar cortex or white matter. Histological examination also showed Aβ parenchymal pathology corresponding to Thal phase 2 and CERAD score 0. Assessment of the neurofibrillary tangle tau pathology and corresponding Braak and Braak stage was not possible due to the severity of primary tauopathy. There was no evidence of additional αsynuclein or TDP-43 pathology.
Discussion
We have described two novel MAPT mutations presenting as FTD with both behavioural symptoms and prominent semantic impairment. Although segregation data is not available for either mutation, both mutations are predicted to be pathogenic, and importantly both are associated with a primary tauopathy at post-mortem.
These patients presented with FTD with behavioural symptoms and cognitive deficits including semantic impairment; previous reports of the phenotype of MAPT mutations are consistent with this e.g. in a large series from Manchester many patients had associated although this was not seen in our two patients.
Age at onset was 45 in case 1, with a disease duration of 9 years, whilst age at onset was 47 in case 2, with a disease duration of 7 years, both of which are consistent with previous reports. In general, patients with an underlying pathogenic MAPT mutation have a mean age at onset in the mid-50s (Snowden et al, 2015) , though onset can be anywhere between the third to the ninth decade. Some mutations tend to cause a more rapidly progressing disease (e.g. P301L) and others a more slowly progressive phenotype (e.g. R406W), although with many cases, like the ones described here, disease duration lies somewhere in between these two extremes.
Although the two mutations described here are novel, mutations close to these sites have previously been shown to be pathogenic. Close to the D252V mutation in exon 9 (in case 1), the K257T mutation has been reported to present in the fifth decade with an amnestic and then behavioural syndrome (Rizzini et al. 2000) , in keeping with our patient. Similar to the G389_I392del mutation (in case 2), mutations in the G389R are associated with disease onset Although we do not have segregation data from the families, two main factors argue in favour of the pathogenicity of these variants: both are novel (not present in gnomAD, other databases, or in our in-house exome sequencing data on >3000 samples including healthy controls and non-FTD diagnoses); and both have CADD scores of 21.5 indicating these are predicted to be in the top 1% of the most deleterious variations in the human genome.
In conclusion, these two novel variants are likely to be pathogenic, but the genetic analysis of other family members to establish segregation of the variants with the disease in the families would be essential to establish pathogenicity and the biological analysis of the function of the mutated protein could also provide important information regarding the role of these variants in the disease process. A2, A3, B2 and B3) . The anterior temporal lobe at the level of
